Deep Genomics
AI platform for RNA therapeutics discovery that predicts genetic variant effects and identifies novel drug targets.
What it does
Deep Genomics is an AI-native drug discovery company applying deep learning to RNA biology - using AI to predict how genetic variants affect RNA splicing, gene expression, and protein production, and to design RNA-based therapeutic candidates (antisense oligonucleotides, siRNA) that correct these effects. Its BigRNA platform uses large language models trained on genomic data to predict the impact of any genetic change on RNA processing - enabling the discovery of genetic drivers of disease and design of RNA therapeutics targeting them. Deep Genomics both licenses its AI platform to pharmaceutical partners and runs its own internal pipeline of AI-designed RNA therapeutics.
Why AI-NATIVE
Deep Genomics is AI-native - deep learning models trained on genomic sequence data to predict RNA biology outcomes and design therapeutic candidates are the core product and company architecture.
Best for
Pharmaceutical companies and biotech firms partner with Deep Genomics for RNA therapeutics discovery - AI-powered genetic variant analysis identifying novel disease targets and AI therapeutic design generating candidate molecules for rare genetic diseases.
Limitations
Deep Genomics is focused on RNA biology and RNA therapeutics — pharmaceutical companies working in small molecule, antibody, or gene editing modalities have limited applicable use cases for the platform.
Deep Genomics' AI predicts RNA biology outcomes from sequence data but all therapeutic candidates require extensive experimental validation and clinical testing before any human use.
Deep Genomics is an AI-native drug discovery company with an internal pipeline — the value realization timeline is long and subject to clinical development risk like any drug development program.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| AI generative drug design | Insilico Medicine |
| Genomics and biomarker discovery | BenevolentAI |
| Clinical genomics platform | Benchling |
Deep Genomics operates through pharmaceutical partnership deals and internal pipeline development. Partnership contracts are negotiated milestone-based agreements. Not a commercially available SaaS platform.
